SE506529C2 - Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori - Google Patents

Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori

Info

Publication number
SE506529C2
SE506529C2 SE9600233A SE9600233A SE506529C2 SE 506529 C2 SE506529 C2 SE 506529C2 SE 9600233 A SE9600233 A SE 9600233A SE 9600233 A SE9600233 A SE 9600233A SE 506529 C2 SE506529 C2 SE 506529C2
Authority
SE
Sweden
Prior art keywords
thiocyanate
lactoperoxidase
preparation
peroxide
peroxide donor
Prior art date
Application number
SE9600233A
Other languages
English (en)
Swedish (sv)
Other versions
SE9600233D0 (sv
SE9600233L (sv
Inventor
Carl Olof Claesson
Gustaf Lindewald
Original Assignee
Semper Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semper Ab filed Critical Semper Ab
Priority to SE9600233A priority Critical patent/SE506529C2/sv
Publication of SE9600233D0 publication Critical patent/SE9600233D0/xx
Priority to EP97901880A priority patent/EP1007086B1/de
Priority to CA002243708A priority patent/CA2243708C/en
Priority to AT97901880T priority patent/ATE220556T1/de
Priority to JP9526782A priority patent/JP2000509367A/ja
Priority to DE69714083T priority patent/DE69714083T2/de
Priority to AU15627/97A priority patent/AU731221B2/en
Priority to PCT/SE1997/000098 priority patent/WO1997026908A1/en
Priority to US09/117,029 priority patent/US6149908A/en
Publication of SE9600233L publication Critical patent/SE9600233L/xx
Publication of SE506529C2 publication Critical patent/SE506529C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/03—Oxidoreductases acting on the CH-OH group of donors (1.1) with a oxygen as acceptor (1.1.3)
    • C12Y101/03004—Glucose oxidase (1.1.3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01007—Peroxidase (1.11.1.7), i.e. horseradish-peroxidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dairy Products (AREA)
  • Confectionery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9600233A 1996-01-23 1996-01-23 Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori SE506529C2 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE9600233A SE506529C2 (sv) 1996-01-23 1996-01-23 Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
US09/117,029 US6149908A (en) 1996-01-23 1997-01-22 Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating Helicobacter pylori infection
JP9526782A JP2000509367A (ja) 1996-01-23 1997-01-22 ヘリコバクタピロリ感染の治療用医薬を製造するためのラクトペルオキシダーゼ、ペルオキシドドナーおよびチオシアネートの使用
CA002243708A CA2243708C (en) 1996-01-23 1997-01-22 Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection
AT97901880T ATE220556T1 (de) 1996-01-23 1997-01-22 Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori
EP97901880A EP1007086B1 (de) 1996-01-23 1997-01-22 Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori
DE69714083T DE69714083T2 (de) 1996-01-23 1997-01-22 Die verwendung von lactoperoxidase, einem peroxiddonor und thiocyanat zur herstellung eines medikaments zur behandlung einer infektion mit helicobacter pylori
AU15627/97A AU731221B2 (en) 1996-01-23 1997-01-22 Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection
PCT/SE1997/000098 WO1997026908A1 (en) 1996-01-23 1997-01-22 Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9600233A SE506529C2 (sv) 1996-01-23 1996-01-23 Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori

Publications (3)

Publication Number Publication Date
SE9600233D0 SE9600233D0 (sv) 1996-01-23
SE9600233L SE9600233L (sv) 1997-07-24
SE506529C2 true SE506529C2 (sv) 1997-12-22

Family

ID=20401114

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9600233A SE506529C2 (sv) 1996-01-23 1996-01-23 Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori

Country Status (9)

Country Link
US (1) US6149908A (de)
EP (1) EP1007086B1 (de)
JP (1) JP2000509367A (de)
AT (1) ATE220556T1 (de)
AU (1) AU731221B2 (de)
CA (1) CA2243708C (de)
DE (1) DE69714083T2 (de)
SE (1) SE506529C2 (de)
WO (1) WO1997026908A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19710068A1 (de) * 1997-03-12 1998-09-17 Kramer Axel Mittel zur Förderung der Mundhygiene und der Mundgesundheit
US5972355A (en) * 1997-09-30 1999-10-26 E-L Management Corp. Stable compositions containing biologically active components
KR100603088B1 (ko) 1997-11-05 2006-07-20 코퍼트 비.브이. 식물 병원성 미생물에 대한 살충제
US6190667B1 (en) 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
US6399570B1 (en) * 1999-02-05 2002-06-04 Agennix, Inc. Antimicrobial/endotoxin neutralizing polypeptide
DE60033019D1 (de) * 1999-03-17 2007-03-08 Morinaga & Co Arzneimittel, nahrungsmittel, getränke und futter enthaltend eine kakao-komponente
US6342528B1 (en) * 2000-01-18 2002-01-29 Lynntech, Inc. Control of microbial populations in the gastrointestinal tract of animals
JP5132865B2 (ja) * 2000-08-21 2013-01-30 ジェド ダブリュ. ファーヒー イソチオシアネートを用いたヘリコバクターの治療方法
WO2002069958A1 (de) * 2001-03-01 2002-09-12 Wolfgang Weuffen Thiocyanationen zur vorbeugung und therapie von bse und ähnlichen erkrankungen beim tier und menschen
US7770577B2 (en) 2001-05-15 2010-08-10 Gregory E Conner Methods and devices for treating lung dysfunction
US6702998B2 (en) * 2001-05-15 2004-03-09 Gregory E. Conner Methods and devices for treating lung dysfunction
SE0200876L (sv) * 2002-03-22 2003-09-23 Krister Tano Nässpray mot öroninflammationer
NZ537089A (en) 2003-02-24 2007-07-27 Morinaga Milk Industry Co Ltd Interleukin 6 production inhibitor
WO2005018701A1 (en) * 2003-08-25 2005-03-03 Kane Biotech Inc. Synergistic antimicrobial compositions and methods of inhibiting biofilm formation
CN100480378C (zh) 2004-02-17 2009-04-22 森永乳业株式会社 生产乳过氧化物酶的方法
US20060289354A1 (en) * 2005-06-15 2006-12-28 Buckman Laboratories International, Inc. Method and composition to control the growth of microorganisms in aqueous systems and on substrates
US20070092502A1 (en) * 2005-09-01 2007-04-26 Allergan, Inc. Method of Treating Glaucoma
AU2006335883B2 (en) * 2006-01-20 2011-04-28 Morinaga Milk Industry Co., Ltd. Pharmaceutical composition, food or drink, or feed for intestinal disease
US20070197388A1 (en) * 2006-02-22 2007-08-23 Buckman Laboratories International, Inc. Haloperoxidase treatment to control algae
EP2081588A1 (de) * 2006-07-03 2009-07-29 Jean-Paul Perraudin Antimikrobielle zusammensetzung und ihre verwendungen
GB0705557D0 (en) * 2007-03-23 2007-05-02 Stead Richard G A treatment
CN101977625A (zh) * 2008-03-20 2011-02-16 克里斯特·坦诺 物质在制备治疗感冒药物中的应用
WO2010042834A1 (en) 2008-10-09 2010-04-15 Anadys Pharmaceuticals, Inc. A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds
JP2009215301A (ja) * 2009-04-27 2009-09-24 Morinaga Milk Ind Co Ltd プロテアーゼ阻害剤
NZ600269A (en) * 2009-05-20 2014-02-28 Dec Int Nz Ltd Delivery device for treatment of mastitis
US20120315261A1 (en) * 2010-02-24 2012-12-13 Morinaga Milk Industry Co., Ltd. Antibacterial auxiliary agent comprising kombu extract as active ingredient, antibacterial composition, and food or beverage
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US8865772B2 (en) 2012-07-26 2014-10-21 The William M. Yarbrough Foundation Method for treating skin cancer
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US20150282489A1 (en) 2012-11-30 2015-10-08 Dsm Ip Assets B.V. Synergistic fungicidal compositions containing lactoperoxidase system
EP3245871A1 (de) * 2014-04-30 2017-11-22 Matoke Holdings Limited Antimikrobielle zusammensetzungen
WO2016059654A1 (en) * 2014-10-16 2016-04-21 Giuseppe Baricco Use of glucose oxidase for the control, the prevention and the cure of intestinal disorders
GB2540130B (en) * 2015-06-29 2021-04-14 Institute Of Tech Sligo A composition and a method for controlling bacterial infection
GB201716986D0 (en) 2017-10-16 2017-11-29 Matoke Holdings Ltd Antimicrobial compositions
EP4309500B1 (de) 2022-07-18 2025-06-04 Acies Bio d.o.o. Biokontrollmittel auf peroxidase-basis
US20250332227A1 (en) 2022-07-18 2025-10-30 Acies Bio D.O.O. Peroxidase based biocontrol agents
GB2635854B (en) * 2023-11-24 2026-03-18 Killian Obriain Composition and use thereof for the treatment of watery mouth disease in lambs

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE420793B (sv) * 1976-03-08 1981-11-02 Astra Ewos Ab Fodermedel innehallande ett antibakteriellt system
US4578265A (en) * 1981-08-13 1986-03-25 Laclede Professional Products, Inc. Di-enzymatic dentifrice
US4564519A (en) * 1983-06-06 1986-01-14 Laclede Professional Products, Inc. Di-enzymatic chewable dentifrice
DK501686A (da) * 1986-10-20 1988-04-21 Otto Melchior Poulsen Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det
SE469004B (sv) * 1989-03-07 1993-04-26 Nobeltech Electronics Ab Nattkikare
FR2646777B1 (fr) * 1989-05-12 1993-09-03 Bio Serae Lab Procede de preparation d'un produit particulaire antimicrobien, produit antimicrobien obtenu et applications
GB9002422D0 (en) * 1990-02-03 1990-04-04 Boots Co Plc Anti-microbial compositions
US5453284A (en) * 1993-01-29 1995-09-26 Pellico; Michael A. Stabilized enzymatic dentifrice
US5336494A (en) * 1993-01-29 1994-08-09 Pellico Michael A Pet chewable products with enzymatic coating

Also Published As

Publication number Publication date
US6149908A (en) 2000-11-21
ATE220556T1 (de) 2002-08-15
AU731221B2 (en) 2001-03-29
CA2243708C (en) 2007-04-24
JP2000509367A (ja) 2000-07-25
DE69714083T2 (de) 2003-03-27
EP1007086B1 (de) 2002-07-17
AU1562797A (en) 1997-08-20
SE9600233D0 (sv) 1996-01-23
SE9600233L (sv) 1997-07-24
CA2243708A1 (en) 1997-07-31
DE69714083D1 (de) 2002-08-22
WO1997026908A1 (en) 1997-07-31
EP1007086A1 (de) 2000-06-14

Similar Documents

Publication Publication Date Title
AU731221B2 (en) Use of lactoperoxidase, a peroxide donor and thiocyanate for the manufacture of a medicament for treating helicobacter pylori infection
US4762702A (en) Pharmaceutical preparation containing ibuprofen and a process for its preparation
RU2385736C2 (ru) Композиции, содержащие липазу, протеазу и амилазу, предназначенные для лечения недостаточности поджелудочной железы
US6350468B1 (en) Double capsule for the administration of active principles in multiple therapies
US10596235B2 (en) Pharmaceutical preparation
US5260280A (en) Bacterial toxin neutralizer
EP0828509A1 (de) Zusammensetzungen zur verbesserung der verdaulichkeit und ausnutzung von nähestoffen
CN1901924B (zh) 用于抑制细菌定居的方法
RU2104710C1 (ru) Фармацевтические бактериоциновые композиции и их применение
JP2002525266A (ja) 感染性潰瘍又は胃炎に対するタウロリジン及び/又はタウルルタム
WO2019026997A1 (ja) 可食性フィルム
JP2002085009A (ja) 納豆末を用いた腸内活性化食品
JP7554807B2 (ja) 消化障害の予防および/または処置用の医薬組成物およびそれを製造する方法、並びにそれを含む医薬製品
JP3854657B2 (ja) 腸管保護剤
JPH11158075A (ja) 膵機能調節剤
Slomiany et al. Suppression of Helicobacter pylori urease activity by sucralfate and sulglycotide
RU2149008C1 (ru) Способ получения биопрепарата
JPH07179355A (ja) IgGおよびIgMクラスの抗体産生を促進する 免疫賦活剤
JP2761815B2 (ja) 酪酸菌の液剤
JP2003073278A (ja) 抗ヘリコバクターピロリ剤
JP3212364B2 (ja) 新規なローヤルゼリー配合物
JPH10130164A (ja) 胃腸障害予防及び/又は治療剤
RU2325166C1 (ru) Фармацевтическая композиция антибиотиков и лактулозы для профилактики энтеральных дисбиозов в процессе антибиотикотерапии
EP1043022B1 (de) Hemmer der natrium-ion absorption und beschleuniger der natrium-ion exkretion als wirkstoffe zur vorbeugung oder behandlung von erkrankungen die sich ergeben aus übermässiges einnehmen von kochsalz
JP2002234847A (ja) ヘリコバクター・ピロリ菌抑制剤

Legal Events

Date Code Title Description
NUG Patent has lapsed